- Home
- PDO vs ARWR Comparison
PDO vs ARWR Comparison
Compare PDO & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDO
- ARWR
- Stock Information
- Founded
- PDO 2020
- ARWR 2003
- Country
- PDO United States
- ARWR United States
- Employees
- PDO N/A
- ARWR N/A
- Industry
- PDO Trusts Except Educational Religious and Charitable
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- PDO Finance
- ARWR Health Care
- Exchange
- PDO Nasdaq
- ARWR Nasdaq
- Market Cap
- PDO 1.7B
- ARWR 1.8B
- IPO Year
- PDO N/A
- ARWR 1993
- Fundamental
- Price
- PDO $13.47
- ARWR $16.90
- Analyst Decision
- PDO
- ARWR Buy
- Analyst Count
- PDO 0
- ARWR 8
- Target Price
- PDO N/A
- ARWR $43.71
- AVG Volume (30 Days)
- PDO 520.0K
- ARWR 1.5M
- Earning Date
- PDO 01-01-0001
- ARWR 08-07-2025
- Dividend Yield
- PDO 11.80%
- ARWR N/A
- EPS Growth
- PDO N/A
- ARWR N/A
- EPS
- PDO N/A
- ARWR N/A
- Revenue
- PDO N/A
- ARWR $545,209,000.00
- Revenue This Year
- PDO N/A
- ARWR $21,924.50
- Revenue Next Year
- PDO N/A
- ARWR N/A
- P/E Ratio
- PDO N/A
- ARWR N/A
- Revenue Growth
- PDO N/A
- ARWR 1436.97
- 52 Week Low
- PDO $10.65
- ARWR $9.57
- 52 Week High
- PDO $13.31
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- PDO 56.15
- ARWR 61.55
- Support Level
- PDO $13.32
- ARWR $15.33
- Resistance Level
- PDO $13.49
- ARWR $16.76
- Average True Range (ATR)
- PDO 0.09
- ARWR 0.77
- MACD
- PDO 0.02
- ARWR -0.00
- Stochastic Oscillator
- PDO 93.06
- ARWR 96.10
About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.